Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06842030 · ClinicalTrials.gov registry record · NA
Feasibility Trial of Darwin OncoTreat and OncoTarget Precision Medicine Testing
A NA study, sponsored by Good Samaritan Hospital Medical Center, New York.
- Not yet
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT06842030: Clinical Trial NA study, sponsored by Good Samaritan Hospital Medical Center, New York.
NCT06842030 is a NA study that has not yet begun recruiting, run by Good Samaritan Hospital Medical Center, New York. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06842030, a NA study, has not yet begun recruiting, sponsored by Good Samaritan Hospital Medical Center, New York.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a feasibility trial to assess use of OncoTarget and OncoTreat testing in a basket design of patients with oligmetastasis across various solid tumor histology. Eligible oligometastatic patients that are receiving radiation therapy (n=20) will undergo mandatory tumor biopsy prior to precision medicine testing. Formalin fixed paraffin embedded tissue with \>50% tumor will be sent to the Laboratory of Personalized Genomic Medicine at Columbia University Medical Center for Darwin OncoTarget and OncoTreat testing. This will be supplementing routine clinical care with the goal of improving outcomes. The treating oncologist will decide to administer standard of care systemic therapy or proceed with treatment recommended by precision medicine testing. Feasibility outcomes include the ability to have the OncoTarget and OncoTreat test performed based on tumor type and pathology, ability to procure agents, change in medication use, and identification of unknown barriers. This study is assessing the use of precision medicine in a population has documented poor outcomes with implications aimed at improving these outcomes.
Primary Outcome
Proportion of participants whose tumor biopsy successfully undergoes OncoTarget and OncoTreat testing based on sufficient cellularity/DNA/RNA, defined as \>50% tumor.
Interventions
- DIAGNOSTIC_TEST Darwin OncoTarget and OncoTreat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2027-04-10 |
| Phase | NA |
What is known before NCT06842030 opens enrollment
NCT06842030 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Darwin OncoTarget and OncoTreat is the first listed.
NCT06842030 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06842030 about?
NCT06842030 is a clinical study titled "Feasibility Trial of Darwin OncoTreat and OncoTarget Precision Medicine Testing". This is a feasibility trial to assess use of OncoTarget and OncoTreat testing in a basket design of patients with oligmetastasis across various solid tumor histology. Eligible oligometastatic patients that are receiving radiation therapy (n=20) will undergo mandatory tumor biopsy prior to precision ...
What is the current status of trial NCT06842030?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2025-03-10. Estimated completion is 2027-04-10.
What interventions are being tested in trial NCT06842030?
The interventions under investigation include: Darwin OncoTarget and OncoTreat (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06842030?
This trial is sponsored by Good Samaritan Hospital Medical Center, New York, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06842030's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI